Clinical Trials Logo

AML, Childhood clinical trials

View clinical trials related to AML, Childhood.

Filter by:
  • None
  • Page 1

NCT ID: NCT06389357 Not yet recruiting - Lymphoma Clinical Trials

Return to School Adaptation Programme for Children With Cancer

web-based
Start date: July 1, 2024
Phase: N/A
Study type: Interventional

This study is planned to evaluate the effect of back-to-school adaptation programme on social anxiety score, coping score and back-to-school readiness score in children aged 8-17 years who are followed up with a diagnosis of cancer. H1: Is there a significant difference in children's social anxiety scores before and after the back-to-school adaptation programme? H2: Is there a significant difference in children's coping scores before and after the back-to-school adaptation programme? H3: Is there a significant difference in children's readiness to return to school scores before and after the back-to-school adaptation programme?

NCT ID: NCT06326463 Recruiting - Lymphoma Clinical Trials

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

Start date: July 2024
Phase: Phase 1
Study type: Interventional

The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come back after treatment (relapse). Primary Objective To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD70-CAR T cells in patients (≤21 years) with recurrent/refractory CD70+ hematological malignancies after lymphodepleting chemotherapy. Secondary Objectives To evaluate the antileukemic activity of CD70-CAR T cells. We will determine the anti- leukemic activity of the CD70-CAR T cells in the bone marrow and in the treatment of extramedullary disease.

NCT ID: NCT06316960 Recruiting - Relapse/Recurrence Clinical Trials

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Start date: March 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of avapritinib in relapsed or refractory pediatric core binding factor acute myeloid leukemia with KIT mutation.

NCT ID: NCT06221683 Recruiting - Clinical trials for Acute Myeloid Leukemia

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

GMCAII
Start date: March 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to estimate the rate (probability) of complete remission or complete remission with incomplete count recovery (CR/CRi) with negative MRD after induction I and II, event-free survival (EFS), and cumulative incidence (probability) of relapse (CIR), in patients receiving molecular/precision medicine and MRD-driven remission inductions, and to assess secondarily if there is an improvement over the AML2018 protocol.

NCT ID: NCT06158828 Recruiting - Clinical trials for Acute Myeloid Leukemia

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

ABCD-NK
Start date: May 15, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II pilot study aims to enhance the effectiveness of stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). Patients will undergo a stem cell transplant from a half-matched family donor. One week later, patients will receive an additional infusion of immune cells and a drug called interleukin-2. To mitigate the potential complications associated with graft-versus-host-disease, the donated stem cell product undergoes a process that removes a specific type of immune cell. After transplant, recipients are administered additional immune cells known as memory-like natural killer (ML NK) cells. These cells are derived by converting conventional natural killer cells obtained from the donor. The infusion of a modified stem cell product, along with administration of ML NK cells may help prevent the development of GvHD while simultaneously improving the efficacy of the treatment.

NCT ID: NCT05622591 Withdrawn - Clinical trials for Acute Myeloid Leukemia

ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML

Pediatric AML
Start date: March 2024
Phase: Phase 1
Study type: Interventional

This research study was planned to focus on a rare type of acute myeloid leukemia (with the subtype CBFA2T3::GLIS2 that overexpresses folate receptor alpha (FRα) (a protein on the surface of leukemia cells)) that has relapsed or is refractory. Relapse means the cancer has come back after treatment. Refractory means the cancer does not respond to treatment.

NCT ID: NCT05077423 Terminated - AML, Childhood Clinical Trials

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start date: May 25, 2022
Phase: Phase 1
Study type: Interventional

Pediatric patients (<21 years at study entry) with relapsed or refractory acute myeloid leukemia (AML) will be treated with CD33*CD3 a bispecific antibody to investigate the safety and tolerability of the drug.

NCT ID: NCT04326439 Terminated - Clinical trials for Acute Myeloid Leukemia

AflacLL1901 (CHOA-AML)

Start date: January 24, 2020
Phase: Phase 2
Study type: Interventional

The investigators propose to study an Aflac-AML chemotherapy backbone prospectively to validate its use in all pediatric AML and to further evaluate the cardiotoxicity with this approach for low risk AML.

NCT ID: NCT03825367 Active, not recruiting - AML, Childhood Clinical Trials

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Start date: November 29, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II Study of Nivolumab in Combination with 5-azacytidine in pediatric patients with relapsed/refractory acute myeloid leukemia